[go: up one dir, main page]

BR9608449A - Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. - Google Patents

Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.

Info

Publication number
BR9608449A
BR9608449A BR9608449-9A BR9608449A BR9608449A BR 9608449 A BR9608449 A BR 9608449A BR 9608449 A BR9608449 A BR 9608449A BR 9608449 A BR9608449 A BR 9608449A
Authority
BR
Brazil
Prior art keywords
virus
defective recombinant
pharmaceutical composition
adenoviruses
recombinant virus
Prior art date
Application number
BR9608449-9A
Other languages
English (en)
Inventor
Didier Branellec
Kenneth Walsh
Jeffrey M Isner
Patrice Denefle
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of BR9608449A publication Critical patent/BR9608449A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

"VìRUS RECOMBINANTE DEFEITUOSO, ADENOVìRUS, USO DE UM VìRUS, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a vírus recombinantes defeituosos, que contêm pelo menos um gene inserido codificando toda ou parte da proteína GAX ou de uma variante desta proteína, e a seu uso terapêutico, em particular para tratar restenose pós-angioplástica.
BR9608449-9A 1995-03-31 1996-03-28 Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. BR9608449A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504234A FR2732357B1 (fr) 1995-03-31 1995-03-31 Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
PCT/US1996/004493 WO1996030385A1 (en) 1995-03-31 1996-03-28 Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis

Publications (1)

Publication Number Publication Date
BR9608449A true BR9608449A (pt) 1999-11-30

Family

ID=9477928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608449-9A BR9608449A (pt) 1995-03-31 1996-03-28 Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.

Country Status (16)

Country Link
US (2) US5851521A (pt)
EP (1) EP0817791A4 (pt)
JP (1) JPH11503314A (pt)
KR (1) KR19980703454A (pt)
CN (1) CN1190402A (pt)
AP (1) AP1011A (pt)
AU (1) AU701345B2 (pt)
BR (1) BR9608449A (pt)
CA (1) CA2216878A1 (pt)
CZ (1) CZ308897A3 (pt)
FR (1) FR2732357B1 (pt)
HU (1) HUP9801767A3 (pt)
OA (1) OA10516A (pt)
SI (1) SI9620059A (pt)
SK (1) SK132797A3 (pt)
WO (1) WO1996030385A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
FR2740344B1 (fr) * 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers
FR2754822B1 (fr) * 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
AU3347000A (en) 1999-01-19 2000-08-01 Children's Hospital Of Philadelphia, The Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6730313B2 (en) 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
JP4981229B2 (ja) * 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
US20030100889A1 (en) * 2001-07-05 2003-05-29 Nicolas Duverger Method of administration of a gene of interest to a vascular tissue
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
WO2007068784A1 (en) 2005-12-14 2007-06-21 Licentia Ltd Novel neurotrophic factor protein and uses thereof
US20040220656A1 (en) * 2003-04-30 2004-11-04 Epstein Samuel J. Coated medical devices and methods of making the same
US20080215137A1 (en) * 2003-04-30 2008-09-04 Boston Scientific Scimed, Inc. Therapeutic driving layer for a medical device
CA2538843A1 (en) * 2003-09-12 2005-03-24 Vertex Pharmaceuticals Incorporated Animal model for protease activity and liver damage
AU2005222384A1 (en) 2004-03-05 2005-09-22 Vegenics Limited Growth factor binding constructs materials and methods
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) * 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
FI20050753L (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
WO2006101629A2 (en) * 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
AU2006279462A1 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified VEGF and PDGF with improved angiogenic properties
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
ES2497641T3 (es) 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
EP2241626B1 (en) 2008-01-09 2016-01-06 Konkuk University Industrial Cooperation Corp Baculovirus-based vaccines
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JP2011526916A (ja) 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
WO2011055888A1 (en) 2009-11-06 2011-05-12 Chung-Ang University Industry-Academy Cooperation Foundtion Nanoparticle-based gene delivery systems
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
US8975029B2 (en) 2011-05-19 2015-03-10 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
WO2013077645A1 (ko) 2011-11-24 2013-05-30 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
DK2785683T3 (da) 2011-11-30 2020-04-14 Ludwig Inst For Cancer Res Ltd Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
PL3421602T3 (pl) 2012-09-06 2021-10-25 The University Of Chicago Polinukleotydy antysensowne wywołujące pominięcie egzonu i sposoby leczenia dystrofii
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
RU2699007C2 (ru) 2013-02-18 2019-09-02 Ведженикс Пти Лимитед Молекулы, связывающие лиганды, и их применение
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
ES2846902T3 (es) 2015-04-08 2021-07-30 Univ Chicago Composiciones y procedimientos para corregir la distrofia muscular de cinturas tipo 2C mediante omisión de exones
WO2017065497A1 (ko) 2015-10-12 2017-04-20 한양대학교 산학협력단 유전자 전달 및 유전자 치료를 위한 아데노바이러스 복합체
AR109539A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Sitio de inserción orf70 de ehv
JP7187448B2 (ja) 2016-09-20 2022-12-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 新しいプロモーター
WO2018054822A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
HUE064133T2 (hu) 2016-09-20 2024-03-28 Boehringer Ingelheim Vetmedica Gmbh Kutya adenovírus vektor
CN111630159A (zh) 2017-12-13 2020-09-04 基因药物株式会社 重组腺病毒及包含此病毒的干细胞
BR112020025203A2 (pt) 2018-06-11 2021-03-09 University Of Florida Research Foundation, Inc. Materiais e métodos para tratar distúrbios relacionados o estresse e câncer
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69333886T2 (de) * 1992-11-18 2006-07-27 Arch Development Corp., Chicago Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
EP1024198A3 (en) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
NZ269156A (en) * 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene

Also Published As

Publication number Publication date
SK132797A3 (en) 1998-07-08
US5851521A (en) 1998-12-22
FR2732357B1 (fr) 1997-04-30
CZ308897A3 (cs) 1998-03-18
EP0817791A4 (en) 1998-07-15
AU5531596A (en) 1996-10-16
HUP9801767A2 (hu) 1998-10-28
OA10516A (en) 2002-04-22
CN1190402A (zh) 1998-08-12
SI9620059A (sl) 1998-06-30
FR2732357A1 (fr) 1996-10-04
KR19980703454A (ko) 1998-11-05
CA2216878A1 (en) 1996-10-03
AU701345B2 (en) 1999-01-28
AP1011A (en) 2001-09-22
AP9701117A0 (en) 1996-03-28
JPH11503314A (ja) 1999-03-26
HUP9801767A3 (en) 1999-04-28
USRE37933E1 (en) 2002-12-10
WO1996030385A1 (en) 1996-10-03
EP0817791A1 (en) 1998-01-14
MX9707549A (es) 1998-07-31

Similar Documents

Publication Publication Date Title
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
BR9812134A (pt) Composição farmacêutica para tratamento de dismenorréia e parto prematuro
BR9909472A (pt) Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
FI954654A7 (fi) Aminosokeri- ja glykosaminoglykaanikoostumus sidekudosvauroiden hoitoo n ja korjaukseen
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
DE69534165D1 (de) Adenovirus mit glutathion peroxydate gene
DK1068241T3 (da) Antistofvarianter og fragmenter deraf
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
FR2704556B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
ATE285219T1 (de) Rekombinante haarbehandlungsmittel
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
PT687184E (pt) Adenovirus recombinantes e sua utilizacao em terapia genica para o tratamento de patologias oculares
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
HU9400290D0 (en) Pharmaceutical composition for preventing and treating retinal dieases
BR9611206A (pt) Utilização da proteína gax ou de uma variante da mesma e de pelo menos uma sequência nucleica que codifica completamente ou em parte a proteína gax ou de uma variante da mesma
BR9713514A (pt) Novo uso de creatina
ATE218881T1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
IT1294967B1 (it) Composizione immunogenica da tlp
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]